INNOVATE Corp. Announces Fourth Quarter and Full Year 2021 Results
- Infrastructure: DBM Global delivers record revenue of
- Life Sciences: R2 started shipping
- Spectrum: Broadcasting expands footprint into 12 new designated market areas -
Financial Summary
(in millions, except per share amounts) | Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||
2021 | 2020 | Increase / (Decrease) | 2021 | 2020 | Increase / (Decrease) | |||||||||||||||||
Revenue | $ | 394.8 | $ | 178.0 | 121.8 | % | $ | 1,205.2 | $ | 716.9 | 68.1 | % | ||||||||||
Net loss attributable to common stock and participating preferred stockholders | $ | (5.2 | ) | $ | (7.1 | ) | 26.8 | % | $ | (229.7 | ) | $ | (95.6 | ) | (140.3 | )% | ||||||
Diluted loss per share - Net loss attributable to common stock and participating preferred shareholders | $ | (0.07 | ) | $ | (0.11 | ) | 36.4 | % | $ | (2.98 | ) | $ | (1.88 | ) | (58.5 | )% | ||||||
Total Adjusted EBITDA(1) | $ | 22.1 | $ | 10.0 | 121.0 | % | $ | 43.9 | $ | 25.5 | 72.2 | % |
(1) Reconciliation of GAAP to Non-GAAP measures follows
(2) Note that Total Adjusted EBITDA excludes results for discontinued operations
Commentary
“2021 was a record year for INNOVATE as our strategic transformation continues. We have made excellent progress across all three of our operating segments and have continued that strong momentum into 2022,” said
“We delivered strong fourth quarter financial results which capped a successful year for INNOVATE,” said
Fourth Quarter 2021 Highlights and Recent Highlights
- The Company achieved revenue and Adjusted EBITDA growth of 121.8% and 121.0%, respectively.
- Broadcasting extended the maturity on the
$52 million of outstanding debt to November of 2022 and repurchased the approximately$2 million of debt outstanding at DTV using proceeds from non-core station sales.
Infrastructure
- DBM Global achieved record revenue as demand in the commercial and industrial construction markets remained strong in the fourth quarter.
- For the fourth quarter of 2021, DBM Global reported revenue of
$383.4 million , an increase of 129.6% compared to$167.0 million in the prior year quarter. Net Income was$8.6 million , compared to$2 .8 million for the prior year quarter. Adjusted EBITDA increased to$28 .8 million from$17 .4 million in the prior year quarter. - DBM Global’s total backlog increased to
$1,580.9 million as ofDecember 31, 2021 , up from$394 .5 million as ofDecember 31, 2020 . Taking into consideration awarded, but not yet signed contracts, backlog would have been approximately$1 ,875 million at the end of the fourth quarter of 2021, compared to $608 million at the end of the fourth quarter of 2020.
Life Sciences
- R2 started shipping the
Glacial Spa product toChina , in anticipation of its upcoming launch inChina .
Spectrum
- In January, Broadcasting completed the construction of 21 new broadcast stations, adding 12 new designated market areas to Broadcasting’s already extensive coverage area.
- In the fourth quarter of 2021, Broadcasting renewed carriage agreements with long-standing clients such as Sony Media’s GetTV and LATV network, among others.
- Altogether, today there are more than 70 networks using the Broadcasting distribution platform sponsored by a broad range of media companies that include
CBS ,NBC Universal , Scripps, Weigel, Freemantle, Qurate, Cisneros Media, and beIN Sports, along with others. - Broadcasting increased distribution for beIN Sports XTRA, both the English and Spanish networks, in more than a dozen new markets. beIN Sports XTRA is 24/7 networks offering the most comprehensive, free ad-supported live sports programming “over the air”. Today the English EXTRA network is carried on 157 Broadcasting stations and the Spanish XTRA network, which launched on
September 1, 2021 , is now on 135 Broadcasting stations. - For the fourth quarter of 2021, Broadcasting reported revenue of
$10.7 million , a decrease of 2.7% compared to$11 .0 million in the prior year quarter. The decrease was primarily driven by lower advertising revenue at the Broadcasting network business. - For the fourth quarter of 2021, Broadcasting reported Net Loss of
$3.3 million compared to Net Income$10.0 million in the prior year quarter. Prior year results included$16.6 million of gains on the sale of stations. Adjusted EBITDA was$1 .6 million, compared to an Adjusted EBITDA of$1 .2 million in the prior year quarter. Broadcasting’s results for the quarter reflect the significant efforts to improve operations and reduce costs across the platform, the sale of high-cost non-core stations and the growth in revenues described above, which led to the fifth consecutive quarter of positive Adjusted EBITDA. - As of
December 31, 2021 , Broadcasting operated 238 stations, of which 224 are currently connected to its CentralCast system. The total Broadcasting footprint includes operating stations in 103 markets in theU.S. andPuerto Rico , including operating stations in 34 of the top 35 DMAs.
Fourth Quarter and Full Year Financial Highlights
- Revenue: For the fourth quarter of 2021, INNOVATE consolidated revenue from continuing operations was
$394.8 million , an increase of 121.8% compared to$178.0 million for the prior year quarter. The increase in revenue was due primarily to the Company’s Infrastructure segment, driven by the contribution from Banker Steel, which was acquired in the second quarter of 2021, as well as from higher revenues across DBM Global’s service offerings attributable to timing of project work under execution and backlog mix. For the full year 2021, consolidated net revenue was$1,205.2 million compared to$716.9 million in 2020.
REVENUE by OPERATING SEGMENT | |||||||||||||||||||
(in millions) | Three Months Ended |
Twelve Months Ended |
|||||||||||||||||
2021 | 2020 | Increase / (Decrease) | 2021 | 2020 | Increase / (Decrease) | ||||||||||||||
Infrastructure | $ | 383.4 | $ | 167.0 | $ | 216.4 | $ | 1,159.7 | $ | 676.6 | $ | 483.1 | |||||||
Life Sciences | 0.7 | — | 0.7 | 3.5 | — | 3.5 | |||||||||||||
Spectrum | 10.7 | 11.0 | (0.3 | ) | 42.0 | 40.3 | 1.7 | ||||||||||||
Consolidated INNOVATE | $ | 394.8 | $ | 178.0 | $ | 216.8 | $ | 1,205.2 | $ | 716.9 | $ | 488.3 |
- Net Income (Loss): For the fourth quarter of 2021, INNOVATE reported a Net Loss attributable to common stock and participating preferred stockholders of
$5 .2 million, or$0.07 per fully diluted share, compared to a Net Loss of$7 .1 million, or$0.11 per fully diluted share, for the prior year quarter. For the full year 2021, Net Loss attributable to common and participating preferred stockholders was$229.7M , or$2.98 per fully diluted share, compared to a Net Loss of$95 .6 million, or$1.88 per fully diluted share, in the full year 2020. The increase in the Net Loss was driven by Income (Loss) from Discontinued Operations as a result of the sale of the Insurance segment in 2021. The increase from discontinued operations was offset in part by the gain from the sale of Beyond6 in 2021 and the loss recognized on the sale ofGlobal Marine System Limited recorded during 2020. Continuing operations further contributed to the increased loss due to the gain on the sale of INNOVATE’s 30% interest in the Huawei Marine joint venture, net of the associated tax expense, and was offset in part by a reduction in INNOVATE’s interest expense attributable to the 2021 refinancing of our senior secured debt, as well as from the Infrastructure segment, driven by the contribution from Banker Steel, which was acquired in the second quarter of 2021.
NET INCOME (LOSS) by OPERATING SEGMENT | ||||||||||||||||||||||||
(in millions) | Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||||
2021 | 2020 | Increase / (Decrease) | 2021 | 2020 | Increase / (Decrease) | |||||||||||||||||||
Infrastructure | $ | 8.6 | $ | 2.8 | $ | 5.8 | $ | 16.9 | $ | 6.8 | $ | 10.1 | ||||||||||||
Life Sciences | (6.2 | ) | (5.7 | ) | (0.5 | ) | (19.8 | ) | (14.4 | ) | (5.4 | ) | ||||||||||||
Spectrum | (3.3 | ) | 10.0 | (13.3 | ) | (12.9 | ) | (13.8 | ) | 0.9 | ||||||||||||||
Non-operating Corporate | (6.2 | ) | (18.2 | ) | 12.0 | (64.2 | ) | (90.2 | ) | 26.0 | ||||||||||||||
Other and Eliminations | 2.4 | (0.6 | ) | 3.0 | 2.4 | 68.0 | (65.6 | ) | ||||||||||||||||
Net (loss) income attributable to |
$ | (4.7 | ) | $ | (11.7 | ) | $ | 7.0 | $ | (77.6 | ) | $ | (43.6 | ) | $ | (34.0 | ) | |||||||
Net (loss) income from discontinued operations | — | 7.0 | (7.0 | ) | (149.9 | ) | (48.4 | ) | (101.5 | ) | ||||||||||||||
Net loss attributable to |
$ | (4.7 | ) | $ | (4.7 | ) | — | (227.5 | ) | (92.0 | ) | (135.5 | ) | |||||||||||
Less: Preferred dividends and deemed dividends from conversions | 0.5 | 2.4 | (1.9 | ) | 2.2 | 3.6 | (1.4 | ) | ||||||||||||||||
Net loss attributable to common stock and participating preferred stockholders | $ | (5.2 | ) | $ | (7.1 | ) | $ | 1.9 | $ | (229.7 | ) | $ | (95.6 | ) | $ | (134.1 | ) |
- Adjusted EBITDA: For the fourth quarter of 2021, Total Adjusted EBITDA, which excludes discontinued operations, was
$22.1 million , compared to Total Adjusted EBITDA of$10 .0 million for the prior year quarter. The increase in fourth quarter Adjusted EBITDA can be attributed to the contribution from Banker Steel at the Infrastructure segment, which was acquired in the second quarter of 2021, as well as the equity investment in the Huawei Marine joint venture, as it produced higher income than in the comparable period, which is generally attributable to the timing of turnkey project work. The increase was partially offset from continued pressure on the Industrials business, the completion of a highly profitable project at the design business in the 3rd quarter and modest increases in overhead expenses at Infrastructure and an increase in bonus expense at Non-operating Corporate. For the full year 2021, Total Adjusted EBITDA, was$43.9 million , compared to$25.5 million in 2020.
ADJUSTED EBITDA by OPERATING SEGMENT | ||||||||||||||||||||||||
(in millions) | Three Months Ended |
Twelve Months Ended |
||||||||||||||||||||||
2021 | 2020 | Increase / (Decrease) | 2021 | 2020 | Increase/(Decrease) | |||||||||||||||||||
Infrastructure | $ | 28.8 | $ | 17.4 | $ | 11.4 | $ | 78.4 | $ | 63.2 | $ | 15.2 | ||||||||||||
Life Sciences | (8.2 | ) | (7.9 | ) | (0.3 | ) | (27.6 | ) | (22.5 | ) | (5.1 | ) | ||||||||||||
Spectrum | 1.6 | 1.2 | 0.4 | 6.9 | (1.2 | ) | 8.1 | |||||||||||||||||
Non-operating Corporate | (4.5 | ) | (3.3 | ) | (1.2 | ) | (18.0 | ) | (15.6 | ) | (2.4 | ) | ||||||||||||
Other and Eliminations | 4.4 | 2.6 | 1.8 | 4.2 | 1.6 | 2.6 | ||||||||||||||||||
Total Adjusted EBITDA | $ | 22.1 | $ | 10.0 | $ | 12.1 | $ | 43.9 | $ | 25.5 | $ | 18.4 |
- Balance Sheet: As of
December 31, 2021 , INNOVATE had cash and cash equivalents of$45.5 million compared to$43.8 million as ofDecember 31, 2020 . On a stand-alone basis, as ofDecember 31, 2021 , the Corporate segment had cash and cash equivalents of$22.0 million compared to$27.5 million atDecember 31, 2020 .
Conference Call
INNOVATE will host a live conference call to discuss its fourth quarter and full year 2021 financial results and operations today at
- Live Webcast and Call. A live webcast of the conference call can be accessed by interested parties through the Investor Relations section of the INNOVATE website at innovate-ir.com.
- Dial-in: 1-877-705-6003 (Domestic Toll Free) / 1-201-493-6725 (Toll/International)
- Participant Entry Number: 13726780
- Conference Replay*
- Dial-in: 1-844-512-2921 (Domestic Toll Free) / 1-412-317-6671 (Toll/International)
- Conference Number: 13726780
*Available approximately two hours after the end of the conference call through
About
Contacts
Investor Contact:
ir@innovatecorp.com
(212) 235-2691
Media Contact:
Reevemark
INNOVATE.Team@reevemark.com
(212) 433-4600
Non-GAAP Financial Measures
In this press release, INNOVATE refers to certain financial measures that are not presented in accordance with
Adjusted EBITDA
Management believes that Adjusted EBITDA provides investors with meaningful information for gaining an understanding of our results as it is frequently used by the financial community to provide insight into an organization’s operating trends and facilitates comparisons between peer companies, since interest, taxes, depreciation, amortization and the other items listed in the definition of Adjusted EBITDA below can differ greatly between organizations as a result of differing capital structures and tax strategies. Adjusted EBITDA can also be a useful measure of a company’s ability to service debt. While management believes that non-
The calculation of Adjusted EBITDA, as defined by us, consists of Net income (loss) as adjusted for discontinued operations; depreciation and amortization; Other operating (income) expense, which is inclusive of (gain) loss on sale or disposal of assets, lease termination costs, asset impairment expense and
Management recognizes that using Adjusted EBITDA as a performance measure has inherent limitations as an analytical tool as compared to net income (loss) or other GAAP financial measures, as these non-GAAP measures exclude certain items, including items that are recurring in nature, which may be meaningful to investors.
Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, "forward-looking statements." Generally, forward-looking statements include information describing actions, events, results, strategies and expectations and are generally identifiable by use of the words “believes,” “expects,” “intends,” “anticipates,” “plans,” “seeks,” “estimates,” “projects,” “may,” “will,” “could,” “might,” or “continues” or similar expressions. Such forward-looking statements are based on current expectations and inherently involve certain risks, assumptions and uncertainties. The forward-looking statements in this presentation include, without limitation, any statements regarding INNOVATE’s inability to predict the extent to which the COVID-19 pandemic and related impacts will continue to adversely impact INNOVATE’s business operations, financial performance, results of operations, financial position, the prices of INNOVATE’s securities and the achievement of INNOVATE’s strategic objectives, and changes in macroeconomic and market conditions and market volatility (including developments and volatility arising from the COVID-19 pandemic), including interest rates, the value of securities and other financial assets, and the impact of such changes and volatility on INNOVATE’s financial position. Such statements are based on the beliefs and assumptions of INNOVATE’s management and the management of INNOVATE’s subsidiaries and portfolio companies.
The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance, results or the creation of stockholder value and the Company’s actual results could differ materially from those expressed or implied in the forward-looking statements due to a variety of important factors, both positive and negative, including those that may be identified in subsequent statements and reports filed with the
Although INNOVATE believes its expectations and assumptions regarding its future operating performance are reasonable, there can be no assurance that the expectations reflected herein will be achieved. These risks and other important factors discussed under the caption “Risk Factors” in our most recent Annual Report on Form 10-K filed with the
You should not place undue reliance on forward-looking statements. All forward-looking statements attributable to INNOVATE or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. All such statements speak only as of the date made, and unless legally required, INNOVATE undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(1)
(in millions, except per share amounts)
(Unaudited) | ||||||||||||||||
Three Months Ended |
Twelve Months Ended |
|||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue | $ | 394.8 | $ | 178.0 | $ | 1,205.2 | $ | 716.9 | ||||||||
Cost of revenue | 333.1 | 140.8 | 1,021.5 | 588.5 | ||||||||||||
Gross profit | 61.7 | 37.2 | 183.7 | 128.4 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 47.4 | 36.3 | 168.3 | 145.5 | ||||||||||||
Depreciation and amortization | 7.8 | 4.4 | 25.4 | 17.7 | ||||||||||||
Other operating loss (gain) | (0.4 | ) | (13.8 | ) | 0.6 | (6.5 | ) | |||||||||
Loss from operations | 6.9 | 10.3 | (10.6 | ) | (28.3 | ) | ||||||||||
Other (expense) income: | ||||||||||||||||
Interest expense | (12.5 | ) | (18.6 | ) | (59.1 | ) | (74.8 | ) | ||||||||
Loss on early extinguishment or restructuring of debt | — | (0.2 | ) | (12.5 | ) | (9.4 | ) | |||||||||
Loss from equity investees | 2.0 | 0.6 | (2.8 | ) | (3.4 | ) | ||||||||||
Other income (expense) | (0.1 | ) | (3.8 | ) | 4.3 | 69.2 | ||||||||||
Loss from continuing operations before income taxes | (3.7 | ) | (11.7 | ) | (80.7 | ) | (46.7 | ) | ||||||||
Income tax expense | (1.8 | ) | (3.3 | ) | (5.6 | ) | (7.0 | ) | ||||||||
Loss from continuing operations | (5.5 | ) | (15.0 | ) | (86.3 | ) | (53.7 | ) | ||||||||
Loss from discontinued operations (including loss on sale of |
— | 7.0 | (149.9 | ) | (48.4 | ) | ||||||||||
Net loss | (5.5 | ) | (8.0 | ) | (236.2 | ) | (102.1 | ) | ||||||||
Net loss attributable to noncontrolling interest and redeemable noncontrolling interest | 0.8 | 3.3 | 8.7 | 10.1 | ||||||||||||
Net loss attributable to |
(4.7 | ) | (4.7 | ) | (227.5 | ) | (92.0 | ) | ||||||||
Less: Preferred dividends and deemed dividends from conversions | 0.5 | 2.4 | 2.2 | 3.6 | ||||||||||||
Net loss attributable to common stock and participating preferred stockholders | $ | (5.2 | ) | $ | (7.1 | ) | $ | (229.7 | ) | $ | (95.6 | ) | ||||
Loss per common share - continuing operations | ||||||||||||||||
Basic | $ | (0.07 | ) | $ | (0.22 | ) | $ | (1.05 | ) | $ | (1.25 | ) | ||||
Diluted | $ | (0.07 | ) | $ | (0.22 | ) | $ | (1.05 | ) | $ | (1.25 | ) | ||||
Loss per common share - discontinued operations | ||||||||||||||||
Basic | $ | — | $ | 0.11 | $ | (1.93 | ) | $ | (0.63 | ) | ||||||
Diluted | $ | — | $ | 0.11 | $ | (1.93 | ) | $ | (0.63 | ) | ||||||
Loss per share - Net loss attributable to common stock and participating preferred stockholders | ||||||||||||||||
Basic | $ | (0.07 | ) | $ | (0.11 | ) | $ | (2.98 | ) | $ | (1.88 | ) | ||||
Diluted | $ | (0.07 | ) | $ | (0.11 | ) | $ | (2.98 | ) | $ | (1.88 | ) | ||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 77.3 | 61.2 | 77.1 | 50.3 | ||||||||||||
Diluted | 77.3 | 61.2 | 77.1 | 50.3 | ||||||||||||
(1) The financial statements for the twelve months ended
CONDENSED CONSOLIDATED BALANCE SHEET(1)
(in millions, except share amounts)
2021 |
2020 |
|||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 45.5 | $ | 43.8 | ||||
Accounts receivable, net | 247.1 | 134.7 | ||||||
Contract assets | 118.6 | 86.6 | ||||||
Inventory | 17.0 | 9.9 | ||||||
Restricted cash | 2.0 | 1.5 | ||||||
Assets held for sale | 1.5 | 5,942.1 | ||||||
Other current assets | 10.9 | 8.7 | ||||||
Total current assets | 442.6 | 6,227.3 | ||||||
Investments | 56.0 | 55.4 | ||||||
Deferred tax asset | 3.0 | 3.0 | ||||||
Property, plant and equipment, net | 169.9 | 112.8 | ||||||
127.4 | 111.0 | |||||||
Intangibles, net | 208.4 | 172.1 | ||||||
Other assets | 73.3 | 42.2 | ||||||
Total assets | $ | 1,080.6 | $ | 6,723.8 | ||||
Liabilities, temporary equity and stockholders’ (deficit) equity | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 179.2 | $ | 69.7 | ||||
Accrued liabilities | 93.4 | 77.1 | ||||||
Current portion of debt obligations | 69.5 | 433.6 | ||||||
Contract liabilities | 79.1 | 33.2 | ||||||
Liabilities held for sale | — | 5,306.7 | ||||||
Other current liabilities | 18.3 | 12.9 | ||||||
Total current liabilities | 439.5 | 5,933.2 | ||||||
Deferred tax liability | 9.1 | 7.0 | ||||||
Debt obligations | 556.8 | 127.9 | ||||||
Other liabilities | 63.3 | 39.8 | ||||||
Total liabilities | 1,068.7 | 6,107.9 | ||||||
Commitments and contingencies | ||||||||
Temporary equity | ||||||||
Preferred stock | 18.8 | 10.4 | ||||||
Redeemable noncontrolling interest | 49.3 | 5.3 | ||||||
Total temporary equity | 68.1 | 15.7 | ||||||
Stockholders’ (deficit) equity | ||||||||
Common stock, |
0.1 | 0.1 | ||||||
Shares authorized: 160,000,000 at |
||||||||
Shares issued: 79,225,964 and 77,836,586 at |
||||||||
Shares outstanding: 77,836,748 and 76,726,835 at |
||||||||
Additional paid-in capital | 330.6 | 355.7 | ||||||
(5.2 | ) | (4.2 | ) | |||||
Accumulated deficit | (416.2 | ) | (188.7 | ) | ||||
Accumulated other comprehensive income | 6.4 | 396.9 | ||||||
(84.3 | ) | 559.8 | ||||||
Noncontrolling interest | 28.1 | 40.4 | ||||||
Total stockholders’ (deficit) equity | (56.2 | ) | 600.2 | |||||
Total liabilities, temporary equity and stockholders’ (deficit) equity | $ | 1,080.6 | $ | 6,723.8 |
(1) The financial statements as of
RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA
(Unaudited)
(in millions) | Three Months ended |
||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Elimination | INNOVATE | ||||||||||||||||||
Net (loss) attributable to |
$ | (4.7 | ) | ||||||||||||||||||||
Less: Discontinued operations | — | ||||||||||||||||||||||
Net Income (loss) attributable to |
$ | 8.6 | $ | (6.2 | ) | $ | (3.3 | ) | $ | (6.2 | ) | $ | 2.4 | $ | (4.7 | ) | |||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | |||||||||||||||||||||||
Depreciation and amortization | 6.0 | 0.1 | 1.7 | — | — | 7.8 | |||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 3.8 | — | — | — | — | 3.8 | |||||||||||||||||
Asset impairment expense | — | — | 0.1 | — | — | 0.1 | |||||||||||||||||
— | — | (0.4 | ) | — | — | (0.4 | ) | ||||||||||||||||
(Gain) loss on sale or disposal of assets | 0.3 | — | (0.4 | ) | — | — | (0.1 | ) | |||||||||||||||
Interest expense | 2.2 | — | 2.1 | 8.2 | — | 12.5 | |||||||||||||||||
Other (income) expense, net | 0.2 | — | 1.6 | (1.7 | ) | — | 0.1 | ||||||||||||||||
Income tax expense (benefit) | 6.4 | — | 0.3 | (5.8 | ) | 0.9 | 1.8 | ||||||||||||||||
Noncontrolling interest | 0.9 | (2.2 | ) | (0.4 | ) | — | 0.9 | (0.8 | ) | ||||||||||||||
Share-based compensation expense | — | 0.1 | — | 0.6 | — | 0.7 | |||||||||||||||||
Nonrecurring Items | 0.2 | — | — | — | — | 0.2 | |||||||||||||||||
COVID-19 Costs | 0.3 | — | — | — | — | 0.3 | |||||||||||||||||
Acquisition and disposition costs | (0.1 | ) | — | 0.3 | 0.4 | 0.2 | 0.8 | ||||||||||||||||
Adjusted EBITDA | $ | 28.8 | $ | (8.2 | ) | $ | 1.6 | $ | (4.5 | ) | $ | 4.4 | $ | 22.1 |
(in millions) | Three Months ended |
||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Elimination | INNOVATE | ||||||||||||||||||
Net (loss) attributable to |
$ | (4.7 | ) | ||||||||||||||||||||
Less: Discontinued operations | 7.0 | ||||||||||||||||||||||
Net Income (loss) attributable to |
$ | 2.8 | $ | (5.7 | ) | $ | 10.0 | $ | (18.2 | ) | $ | (0.6 | ) | $ | (11.7 | ) | |||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | |||||||||||||||||||||||
Depreciation and amortization | 2.7 | — | 1.7 | — | — | 4.4 | |||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 2.2 | — | — | — | — | 2.2 | |||||||||||||||||
Asset impairment expense | — | — | 2.6 | — | — | 2.6 | |||||||||||||||||
(Gain) loss on sale or disposal of assets | 0.3 | — | (16.6 | ) | — | — | (16.3 | ) | |||||||||||||||
Interest expense | 2.0 | — | 4.4 | 12.2 | — | 18.6 | |||||||||||||||||
Loss on early extinguishment or restructuring of debt | — | — | — | 0.2 | — | 0.2 | |||||||||||||||||
Other (income) expense, net | 0.5 | (0.1 | ) | 0.6 | 2.9 | — | 3.9 | ||||||||||||||||
Income tax expense (benefit) | 1.7 | — | 0.3 | (1.4 | ) | 2.7 | 3.3 | ||||||||||||||||
Noncontrolling interest | 0.4 | (2.2 | ) | (1.8 | ) | — | 0.3 | (3.3 | ) | ||||||||||||||
Share-based compensation expense | — | 0.1 | — | 0.2 | — | 0.3 | |||||||||||||||||
Nonrecurring Items | 0.5 | — | — | — | — | 0.5 | |||||||||||||||||
COVID-19 Costs | 4.2 | — | — | — | — | 4.2 | |||||||||||||||||
Acquisition and disposition costs | 0.1 | — | — | 0.8 | 0.2 | 1.1 | |||||||||||||||||
Adjusted EBITDA | $ | 17.4 | $ | (7.9 | ) | $ | 1.2 | $ | (3.3 | ) | $ | 2.6 | $ | 10.0 |
(in millions) | Twelve Months ended |
||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Eliminations | INNOVATE | ||||||||||||||||||
Net (loss) attributable to |
$ | (227.5 | ) | ||||||||||||||||||||
Less: Discontinued operations | (149.9 | ) | |||||||||||||||||||||
Net Income (loss) attributable to |
$ | 16.9 | $ | (19.8 | ) | $ | (12.9 | ) | $ | (64.2 | ) | $ | 2.4 | $ | (77.6 | ) | |||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | |||||||||||||||||||||||
Depreciation and amortization | 19.1 | 0.2 | 6.0 | 0.1 | — | 25.4 | |||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 12.2 | — | — | — | — | 12.2 | |||||||||||||||||
Other operating expenses | 0.4 | — | 0.2 | — | — | 0.6 | |||||||||||||||||
Interest expense | 8.5 | — | 9.2 | 41.4 | — | 59.1 | |||||||||||||||||
Other (income) expense, net | (4.0 | ) | — | 3.9 | (4.2 | ) | — | (4.3 | ) | ||||||||||||||
Loss on early extinguishment or restructuring of debt | 1.5 | — | 1.0 | 10.0 | — | 12.5 | |||||||||||||||||
Income tax expense (benefit) | 10.5 | — | 0.3 | (6.1 | ) | 0.9 | 5.6 | ||||||||||||||||
Noncontrolling interest | 1.8 | (8.2 | ) | (2.3 | ) | — | — | (8.7 | ) | ||||||||||||||
Share-based compensation expense | — | 0.2 | 0.6 | 1.6 | — | 2.4 | |||||||||||||||||
Nonrecurring items | 0.5 | — | — | 0.5 | — | 1.0 | |||||||||||||||||
COVID-19 costs | 8.6 | — | — | — | — | 8.6 | |||||||||||||||||
Acquisition and disposition costs | 2.4 | — | 0.9 | 2.9 | 0.9 | 7.1 | |||||||||||||||||
Adjusted EBITDA | $ | 78.4 | $ | (27.6 | ) | $ | 6.9 | $ | (18.0 | ) | $ | 4.2 | $ | 43.9 |
(in millions) | Twelve Months ended |
||||||||||||||||||||||
Infrastructure | Life Sciences | Spectrum | Non-operating Corporate | Other and Eliminations | INNOVATE | ||||||||||||||||||
Net (loss) attributable to |
$ | (92.0 | ) | ||||||||||||||||||||
Less: Discontinued operations | (48.4 | ) | |||||||||||||||||||||
Net Income (loss) attributable to |
$ | 6.8 | $ | (14.4 | ) | $ | (13.8 | ) | $ | (90.2 | ) | $ | 68.0 | $ | (43.6 | ) | |||||||
Adjustments to reconcile net income (loss) to Adjusted EBITDA: | |||||||||||||||||||||||
Depreciation and amortization | 10.7 | 0.1 | 6.8 | 0.1 | — | 17.7 | |||||||||||||||||
Depreciation and amortization (included in cost of revenue) | 9.1 | — | — | — | — | 9.1 | |||||||||||||||||
Other operating (income) expenses | 0.1 | 0.1 | (6.6 | ) | — | — | (6.4 | ) | |||||||||||||||
Interest expense | 8.5 | — | 14.7 | 51.6 | — | 74.8 | |||||||||||||||||
Loss on early extinguishment or restructuring of debt | — | — | — | 9.4 | — | 9.4 | |||||||||||||||||
Other (income) expense, net | 0.5 | (2.3 | ) | 1.9 | 2.1 | (71.3 | ) | (69.1 | ) | ||||||||||||||
Income tax expense (benefit) | 4.2 | — | 0.3 | 0.2 | 2.3 | 7.0 | |||||||||||||||||
Noncontrolling interest | 0.6 | (6.2 | ) | (5.3 | ) | — | 0.8 | (10.1 | ) | ||||||||||||||
Bonus to be settled in equity | — | — | — | (0.5 | ) | — | (0.5 | ) | |||||||||||||||
Share-based compensation expense | — | 0.2 | 0.3 | 2.4 | — | 2.9 | |||||||||||||||||
Nonrecurring items | 2.7 | — | — | 5.4 | — | 8.1 | |||||||||||||||||
COVID-19 costs | 19.4 | — | — | — | — | 19.4 | |||||||||||||||||
Acquisition and disposition costs | 0.6 | — | 0.5 | 3.9 | 1.8 | 6.8 | |||||||||||||||||
Adjusted EBITDA | $ | 63.2 | $ | (22.5 | ) | $ | (1.2 | ) | $ | (15.6 | ) | $ | 1.6 | $ | 25.5 |
Source: INNOVATE Corp.